Back to Search
Start Over
Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia
- Source :
- Haematologica, Vol 107, Iss 7 (2021)
- Publication Year :
- 2021
- Publisher :
- Ferrata Storti Foundation, 2021.
-
Abstract
- Thrombocytopenia is common in patients with myelofibrosis (MF) and is a well-established adverse prognostic factor. Both of the approved Janus kinase (JAK) inhibitors, ruxolitinib and fedratinib, can worsen thrombocytopenia and have not been evaluated in patients with severe thrombocytopenia (platelet counts
- Subjects :
- Diseases of the blood and blood-forming organs
RC633-647.5
Subjects
Details
- Language :
- English
- ISSN :
- 03906078 and 15928721
- Volume :
- 107
- Issue :
- 7
- Database :
- Directory of Open Access Journals
- Journal :
- Haematologica
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.18d1fcd53bdb4ab4a00ad741474aea14
- Document Type :
- article
- Full Text :
- https://doi.org/10.3324/haematol.2021.279415